Allogene Therapeutics Reports GAAP EPS of -$0.15, Described as In Line

Summary

Allogene Therapeutics reported GAAP earnings per share of -$0.15, which a Seeking Alpha headline describes as in line. The source item carries only the headline, so it gives no reporting period, revenue figures, or comparison to expectations or prior periods.

Timeline

1. Seeking Alpha

   5 Nov 2026, 22:21 UTCSource ↗

   Seeking Alpha reports in a headline that Allogene Therapeutics posted GAAP EPS of -$0.15, described as in line, with no further detail in the item.